Search research articles
Contact Us
Filters
Showing results (521-530 of 568) with videos related to
Page
of 57
Sort By:
European Journal of Haematology
|
May 7, 2024
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study
Olivier Decaux, Jean Fontan, Aurore Perrot, et al.
Blood
|
October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre, Aurore Perrot, Denis Caillot, et al.
Annales De Genetique
|
January 1, 1997
Collaborative study of mosaic tetrasomy 12p or Pallister-Killian syndrome (nineteen fetuses or children)
M Mathieu, C Piussan, F Thepot, et al.
Blood
|
September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
Alexis Caulier, Murielle Roussel, Pierre Morel, et al.
Nature Communications
|
January 10, 2013
Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation
Isabel Romero-Camarero, Xiaoyu Jiang, Yasodha Natkunam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Blood
|
April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditions
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Blood
|
February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
Titouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.
Blood
|
November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.
Leukemia
|
July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B Hebraud, X Leleu, V Lauwers-Cances, et al.
Page
of 57
Search research articles
Search
Showing results (521-530 of 568) with videos related to
Sort By:
Page
of 57
European Journal of Haematology
|
May 7, 2024
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study
Olivier Decaux, Jean Fontan, Aurore Perrot, et al.
Blood
|
October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre, Aurore Perrot, Denis Caillot, et al.
Annales De Genetique
|
January 1, 1997
Collaborative study of mosaic tetrasomy 12p or Pallister-Killian syndrome (nineteen fetuses or children)
M Mathieu, C Piussan, F Thepot, et al.
Blood
|
September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
Alexis Caulier, Murielle Roussel, Pierre Morel, et al.
Nature Communications
|
January 10, 2013
Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation
Isabel Romero-Camarero, Xiaoyu Jiang, Yasodha Natkunam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
Aurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.
Blood
|
April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditions
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Blood
|
February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
Titouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.
Blood
|
November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.
Leukemia
|
July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B Hebraud, X Leleu, V Lauwers-Cances, et al.
Page
of 57